215 related articles for article (PubMed ID: 38187394)
1. Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection.
Osmanoglu Ö; Gupta SK; Almasi A; Yagci S; Srivastava M; Araujo GHM; Nagy Z; Balkenhol J; Dandekar T
Front Immunol; 2023; 14():1285345. PubMed ID: 38187394
[TBL] [Abstract][Full Text] [Related]
2. Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19.
Apostolidis SA; Sarkar A; Giannini HM; Goel RR; Mathew D; Suzuki A; Baxter AE; Greenplate AR; Alanio C; Abdel-Hakeem M; Oldridge DA; Giles JR; Wu JE; Chen Z; Huang YJ; Belman J; Pattekar A; Manne S; Kuthuru O; Dougherty J; Weiderhold B; Weisman AR; Ittner CAG; Gouma S; Dunbar D; Frank I; Huang AC; Vella LA; ; Reilly JP; Hensley SE; Rauova L; Zhao L; Meyer NJ; Poncz M; Abrams CS; Wherry EJ
Front Immunol; 2022; 13():834988. PubMed ID: 35309299
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
5. Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19.
Apostolidis SA; Sarkar A; Giannini HM; Goel RR; Mathew D; Suzuki A; Baxter AE; Greenplate AR; Alanio C; Abdel-Hakeem M; Oldridge DA; Giles J; Wu JE; Chen Z; Huang YJ; Pattekar A; Manne S; Kuthuru O; Dougherty J; Weiderhold B; Weisman AR; Ittner CAG; Gouma S; Dunbar D; Frank I; Huang AC; Vella LA; ; Reilly JP; Hensley SE; Rauova L; Zhao L; Meyer NJ; Poncz M; Abrams CS; Wherry EJ
bioRxiv; 2021 May; ():. PubMed ID: 33972943
[TBL] [Abstract][Full Text] [Related]
6. Deciphering molecular mechanisms of SARS-CoV-2 pathogenesis and drug repurposing through GRN motifs: a comprehensive systems biology study.
Sameni M; Mirmotalebisohi SA; Dehghan Z; Abooshahab R; Khazaei-Poul Y; Mozafar M; Zali H
3 Biotech; 2023 Apr; 13(4):117. PubMed ID: 37070032
[TBL] [Abstract][Full Text] [Related]
7. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.
Strich JR; Ramos-Benitez MJ; Randazzo D; Stein SR; Babyak A; Davey RT; Suffredini AF; Childs RW; Chertow DS
J Infect Dis; 2021 Mar; 223(6):981-984. PubMed ID: 33367731
[TBL] [Abstract][Full Text] [Related]
8. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.
Strich JR; Tian X; Samour M; King CS; Shlobin O; Reger R; Cohen J; Ahmad K; Brown AW; Khangoora V; Aryal S; Migdady Y; Kyte JJ; Joo J; Hays R; Collins AC; Battle E; Valdez J; Rivero J; Kim IH; Erb-Alvarez J; Shalhoub R; Chakraborty M; Wong S; Colton B; Ramos-Benitez MJ; Warner S; Chertow DS; Olivier KN; Aue G; Davey RT; Suffredini AF; Childs RW; Nathan SD
Clin Infect Dis; 2022 Aug; 75(1):e491-e498. PubMed ID: 34467402
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Total network controllability analysis discovers explainable drugs for Covid-19 treatment.
Wei X; Pan C; Zhang X; Zhang W
Biol Direct; 2023 Sep; 18(1):55. PubMed ID: 37670359
[TBL] [Abstract][Full Text] [Related]
11. The Coronavirus Network Explorer: mining a large-scale knowledge graph for effects of SARS-CoV-2 on host cell function.
Krämer A; Billaud JN; Tugendreich S; Shiffman D; Jones M; Green J
BMC Bioinformatics; 2021 May; 22(1):229. PubMed ID: 33941085
[TBL] [Abstract][Full Text] [Related]
12. CD36 mediates SARS-CoV-2-envelope-protein-induced platelet activation and thrombosis.
Tang Z; Xu Y; Tan Y; Shi H; Jin P; Li Y; Teng J; Liu H; Pan H; Hu Q; Cheng X; Ye J; Su Y; Sun Y; Meng J; Zhou Z; Chi H; Wang X; Liu J; Lu Y; Liu F; Dai J; Yang C; Chen S; Liu T
Nat Commun; 2023 Aug; 14(1):5077. PubMed ID: 37604832
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection: implications for immunothrombosis.
Ji W; Chen L; Yang W; Li K; Zhao J; Yan C; You C; Jiang M; Zhou M; Shen X
Cell Biosci; 2022 Feb; 12(1):15. PubMed ID: 35139909
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype.
Bongiovanni D; Klug M; Lazareva O; Weidlich S; Biasi M; Ursu S; Warth S; Buske C; Lukas M; Spinner CD; Scheidt MV; Condorelli G; Baumbach J; Laugwitz KL; List M; Bernlochner I
Cell Death Dis; 2021 Jan; 12(1):50. PubMed ID: 33414384
[TBL] [Abstract][Full Text] [Related]
15. Platelets' morphology, metabolic profile, exocytosis, and heterotypic aggregation with leukocytes in relation to severity and mortality of COVID-19-patients.
Yasseen BA; Elkhodiry AA; El-Messiery RM; El-Sayed H; Elbenhawi MW; Kamel AG; Gad SA; Zidan M; Hamza MS; Al-Ansary M; Abdel-Rahman EA; Ali SS
Front Immunol; 2022; 13():1022401. PubMed ID: 36479107
[TBL] [Abstract][Full Text] [Related]
16. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
Das AB
BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
[TBL] [Abstract][Full Text] [Related]
17. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Vergis N; Phillips R; Cornelius V; Katsarou A; Youngstein T; Cook L; Willicombe M; Pilay C; Shturova T; Almonte M; Charania A; Turner R; Kon OM; Cooke G; Thursz M; Cherlin S; Wason J; Milojkovic D; Innes AJ; Cooper N
Trials; 2021 Apr; 22(1):270. PubMed ID: 33845867
[TBL] [Abstract][Full Text] [Related]
18. Platelets and COVID-19.
Rohlfing AK; Rath D; Geisler T; Gawaz M
Hamostaseologie; 2021 Oct; 41(5):379-385. PubMed ID: 34695854
[TBL] [Abstract][Full Text] [Related]
19. Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent.
Pelzl L; Singh A; Funk J; Witzemann A; Marini I; Zlamal J; Weich K; Abou-Khalel W; Hammer S; Uzun G; Althaus K; Bakchoul T
J Thromb Haemost; 2022 Feb; 20(2):387-398. PubMed ID: 34752677
[TBL] [Abstract][Full Text] [Related]
20. Platelet gene expression and function in patients with COVID-19.
Manne BK; Denorme F; Middleton EA; Portier I; Rowley JW; Stubben C; Petrey AC; Tolley ND; Guo L; Cody M; Weyrich AS; Yost CC; Rondina MT; Campbell RA
Blood; 2020 Sep; 136(11):1317-1329. PubMed ID: 32573711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
